Nucleocytoplasmic fractionation and luciferase reporter assays confirmed increased NF-κB activity in the nucleus of TKI-resistant versus sensitive CML cell lines and CD34+ patient samples. Here, NFKB1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.